

SUPPLEMENTAL MATERIAL

Patterns of Clinical Response in Rollover Adolescent Patients With Alopecia Areata Treated With Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study

Ulrike Blume-Peytavi,¹ Brittany Craiglow,² Ilka Arun Netravali,³ Isabella Doche,⁴ Kazutoshi Harada,⁵ Dalia Wajsbrot,⁶ Gianluca Bonfanti,⁷ Rahmat Ishowo-Adejumo,⁸ Robert Wolk,⁶ Helen Tran⁹

¹Department of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany; ²Department of Dermatology, Yale University, New Haven, CT, USA; ³Department of Dermatology, Stanford University, Stanford, CA, USA; ⁴Department of Dermatology, Universidade de São Paulo, São Paulo, Brazil; ⁵Department of Dermatology, Tokyo Medical University, Tokyo, Japan; ⁶Pfizer Inc., Groton, CT, USA; ⁷Engineering Ingegneria Informatica, Milan, Italy; ⁸Pfizer Inc., Collegeville, PA, USA; ⁹Pfizer Inc., New York, NY, USA

Corresponding author:

Helen Tran, PharmD

Email: Helen.Tran@pfizer.com

Supplemental Figure S1. Study design

	ALLEGRO phase 2b/3			ALLEGRO-LT
	Loading (4 weeks)	Maintenance (20 weeks)	Extension (24 weeks)	Long-term study (36 months)
Group A (N=20)	200 mg	50 mg	50 mg	50 mg
Group B (N=19)	200 mg	30 mg	30 mg	50 mg
Group C (N=18)	50 mg	50 mg	50 mg	50 mg
Group D (N=20)	30 mg	30 mg	30 mg	50 mg
Group E (N=9)	10 mg	10 mg	10 mg	50 mg
Group F ^a (N=10)	Placebo	Placebo	200 mg 50 mg	50 mg
Group G ^a (N=9)	Placebo	Placebo	50 mg	50 mg
<i>De novo group</i> (N=76)				200 mg 50 mg

200/50-mg group (n=30)

50-mg group (n=27)

N values represent the number of adolescents in each group. There were 164 adults in groups A and F (received ritlecitinib 200/50 mg) and 164 adults in groups C and G (received ritlecitinib 50 mg). Figure adapted from Figure 1 of King et al., 2025.¹³

*Data while the patient was on placebo were not included in this analysis; data from patients in Groups F and G were re-baselined from the start of treatment with ritlecitinib.